Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 825

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7A
Chunk 825
---
 S-1 filed July 28, 2023).
  
    4.1
     
    Common
    Stock Purchase Warrant, dated April 28, 2023, between MIRA Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to
    Exhibit 4.2 to Form S-1 filed July 28, 2023).
  
    4.2
     
    Common
    Stock Purchase Warrant from the Company to MIRALOGX, dated November 15, 2023 (incorporated by reference to Exhibit 10.2 to the Current
    Report on Form 8-K filed November 20, 2023).
  
    4.3
     
    Representative’s
    Warrant, dated August 7, 2023 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed August
    7, 2023).
  
    4.4*
     
    Description of Securities of the Registrant
  
    10.1+
     
    2022
    Omnibus Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to Form S-1 filed July 28, 2023).
  
    10.2+
     
    Form
    of Stock Option Award under 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to Form S-1 filed July 28, 2023).
  
    10.3
     
    Form
    of Indemnification Agreement (incorporated by reference to Exhibit 10.3 to Form S-1 filed July 28, 2023).
  
    10.4
     
    Confirmatory
    Patent Assignment and Royalty Agreement, dated November 1, 2021, between SRQ Patent Holdings II, LLC and MIRA Pharmaceuticals, Inc.
    (incorporated by reference to Exhibit 10.4 to Form S-1 filed July 28, 2023).
  
    10.5
     
    Amended
    and Restated Limited License Agreement, dated June 27, 2022, between MIRA Pharmaceuticals, Inc. and MyMD Pharmaceuticals, Inc. (incorporated
    by reference to Exhibit 10.5 to Form S-1 filed July 28,